A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting - IM011-237
Updated: 21 February, 2023 | ClinicalTrials.gov
Print Friendly Summary
Inclusion Criteria - Men and women diagnosed with stable plaque psoriasis for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator. - Deemed by the investigator to be a candidate for phototherapy or systemic therapy. - ≥ 3% of Body Surface Area (BSA) involvement at Screening Visit and Day 1 - Dermatology Life Quality Index (DLQI) score > 5 at Screening Visit and Day 1 Exclusion Criteria: Target Disease Exceptions: - Non-plaque psoriasis (that is, guttate, pustular, erythrodermic, palmoplantar only involvement or drug-induced psoriasis) at Screening Visit or Day 1 Other protocol-defined inclusion/exclusion criteria apply.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
Have questions? Live support is available 24/7 - Call 855-907-3286 or email email@example.com